Abuse-resistant amphetamine prodrugs

Abstract

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Description

CROSS REFERENCE RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. application Ser. No. 11 / 400,304, filed Apr. 10, 2006, which in turn, (a) claims benefit under 35 U.S.C. 119(e) to U.S. Provisional Application Nos. 60 / 669,385 filed Apr. 8, 2005, 60 / 669,386 filed Apr. 8, 2005, 60 / 681,170 filed May 16, 2005, 60 / 756,548 filed Jan. 6, 2006, and 60 / 759,958 filed Jan. 19, 2006; (b) is a continuation-in-part of U.S. application Ser. No. 10 / 857,619 filed Jun. 1, 2004, which claims the benefit of under 35 U.S.C. 119(e) to U.S. Provisional Application Nos. 60 / 473,929 filed May 29, 2003 and 60 / 567,801 filed May 5, 2004; and (c) is a continuation-in-part of U.S. application Ser. No. 10 / 858,526 filed Jun. 1, 2004, which, in turn, is a continuation-in-part of international application PCT / US03 / 05525 filed Feb. 24, 2003, which claims priority to U.S. Provisional Application Nos. 60 / 358,368 filed Feb. 22, 2002 and 60 / 362,082 filed Mar. 7, 2002; application Ser. No. 10 / 858,...

AI Technical Summary

Benefits of technology

The present invention provides amphetamine prodrugs and salts thereof that can be used to treat attention deficit hyperactivity disorder (ADHD) and other disorders such as obesity, cancer-related fatigue, excessive daytime sleepiness, and narcolepsy. The prodrugs are crystalline forms of lisdexamphetamine dimesylate that exhibit controlled release of the active ingredient. The crystalline forms have been found to have improved stability and solubility compared to the amorphous form. The prodrugs can be orally administered and are effective in treating ADHD with reduced side effects. The patent also provides methods for preparing and using the prodrugs.

Problems solved by technology

Because of their stimulating effects, amphetamines, including amphetamine derivatives and analogs, are subject to abuse.

Legitimate amphetamine users that develop drug tolerances are especially susceptible to becoming accidental addicts as they increase dosing in order to counteract their increased tolerance of the prescribed drugs.

Additionally, it is possible for individuals to inappropriately self-administer higher than prescribed quantities of the drug or to alter either the product or the route of administration (e.g., inhalation (snorting), injection, and smoking), potentially resulting in immediate release of the active drug in quantities larger than prescribed.

When taken at higher than prescribed doses, amphetamines can cause temporary feelings of exhilaration and increased energy and mental alertness.

Extended release formulations of amphetamines, e.g., Adderall XR®, have an increased abuse liability relative to the single dose tablets because each tablet of the sustained release formulation contains a higher concentration of amphetamine.

Sustained release formulations may also provide uneven release.

Images